Thomas P Slavin1, Kimberly C Banks1, Darya Chudova1, Geoffrey R Oxnard1, Justin I Odegaard1, Rebecca J Nagy1, Kar Wing Kevin Tsang1, Susan L Neuhausen1, Stacy W Gray1, Massimo Cristofanilli1, Angel A Rodriguez1, Aditya Bardia1, Brian Leyland-Jones1, Mike F Janicek1, Michael Lilly1, Guru Sonpavde1, Christine E Lee1, Richard B Lanman1, Funda Meric-Bernstam1, Razelle Kurzrock1, Jeffrey N Weitzel1. 1. Thomas P. Slavin, Kar Wing Kevin Tsang, Susan L. Neuhausen, Stacy W. Gray, and Jeffrey N. Weitzel, City of Hope, Duarte; Kimberly C. Banks, Darya Chudova, Justin I. Odegaard, Rebecca J. Nagy, Christine E. Lee, and Richard B. Lanman, Guardant Health, Redwood City; Razelle Kurzrock, University of California, San Diego, Moores Cancer Center, San Diego, CA; Geoffrey R. Oxnard, Dana-Farber Cancer Institute; Aditya Bardia, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA; Massimo Cristofanilli, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Angel A. Rodriguez, Houston Methodist Hospital; Funda Meric-Bernstam, The University of Texas MD Anderson Cancer Center, Houston, TX; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mike F. Janicek, Arizona Oncology Associates Gynecology Oncology, Scottsdale, AZ; Michael Lilly, Medical University of South Carolina, Charleston, SC; and Guru Sonpavde, The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL.
Abstract
PURPOSE: To determine the potential for detection of incidental germline cancer predisposition mutations through cell-free DNA (cfDNA) analyses in patients who underwent solid tumor somatic mutation evaluation. PATIENTS AND METHODS: Data were evaluated from 10,888 unselected patients with advanced (stage III/IV) cancer who underwent Guardant360 testing between November 2015 and December 2016. The main outcome was prevalence of putative germline mutations identified among 16 actionable hereditary cancer predisposition genes. RESULTS: More than 50 cancer types were studied, including lung (41%), breast (19%), colorectal (8%), prostate (6%), pancreatic (3%), and ovarian (2%). Average patient age was 63.5 years (range, 18 to 95 years); 43% were male. One hundred and fifty-six individuals (1.4%) had suspected hereditary cancer mutations in 11 genes. Putative germline mutations were more frequent in individuals younger than 50 years versus those 50 years and older (3.0% v 1.2%, respectively; P < .001). Highest yields of putative germline findings were in patients with ovarian (8.13%), prostate (3.46%), pancreatic (3.34%), and breast (2.2%) cancer. Putative germline mutation identification was consistent among 12 individuals with multiple samples. Patients with circulating tumor DNA copy number variation and/or reversion mutations suggestive of functional loss of the wild-type allele in the tumor DNA also are described. CONCLUSION: Detection of putative germline mutations from cfDNA is feasible across multiple genes and cancer types without prior mutation knowledge. Many mutations were found in cancers without clear guidelines for hereditary cancer genetic counseling/testing. Given the clinical significance of identifying hereditary cancer predisposition for patients and their families as well as targetable germline alterations such as in BRCA1 or BRCA2, research on the best way to validate and return potential germline results from cfDNA analysis to clinicians and patients is needed.
PURPOSE: To determine the potential for detection of incidental germline cancer predisposition mutations through cell-free DNA (cfDNA) analyses in patients who underwent solid tumor somatic mutation evaluation. PATIENTS AND METHODS: Data were evaluated from 10,888 unselected patients with advanced (stage III/IV) cancer who underwent Guardant360 testing between November 2015 and December 2016. The main outcome was prevalence of putative germline mutations identified among 16 actionable hereditary cancer predisposition genes. RESULTS: More than 50 cancer types were studied, including lung (41%), breast (19%), colorectal (8%), prostate (6%), pancreatic (3%), and ovarian (2%). Average patient age was 63.5 years (range, 18 to 95 years); 43% were male. One hundred and fifty-six individuals (1.4%) had suspected hereditary cancer mutations in 11 genes. Putative germline mutations were more frequent in individuals younger than 50 years versus those 50 years and older (3.0% v 1.2%, respectively; P < .001). Highest yields of putative germline findings were in patients with ovarian (8.13%), prostate (3.46%), pancreatic (3.34%), and breast (2.2%) cancer. Putative germline mutation identification was consistent among 12 individuals with multiple samples. Patients with circulating tumor DNA copy number variation and/or reversion mutations suggestive of functional loss of the wild-type allele in the tumor DNA also are described. CONCLUSION: Detection of putative germline mutations from cfDNA is feasible across multiple genes and cancer types without prior mutation knowledge. Many mutations were found in cancers without clear guidelines for hereditary cancer genetic counseling/testing. Given the clinical significance of identifying hereditary cancer predisposition for patients and their families as well as targetable germline alterations such as in BRCA1 or BRCA2, research on the best way to validate and return potential germline results from cfDNA analysis to clinicians and patients is needed.
Authors: Tom Walsh; Silvia Casadei; Ming K Lee; Christopher C Pennil; Alex S Nord; Anne M Thornton; Wendy Roeb; Kathy J Agnew; Sunday M Stray; Anneka Wickramanayake; Barbara Norquist; Kathryn P Pennington; Rochelle L Garcia; Mary-Claire King; Elizabeth M Swisher Journal: Proc Natl Acad Sci U S A Date: 2011-10-17 Impact factor: 11.205
Authors: Christopher P Childers; Kimberly K Childers; Melinda Maggard-Gibbons; James Macinko Journal: J Clin Oncol Date: 2017-08-18 Impact factor: 44.544
Authors: F Meric-Bernstam; L Brusco; M Daniels; C Wathoo; A M Bailey; L Strong; K Shaw; K Lu; Y Qi; H Zhao; H Lara-Guerra; J Litton; B Arun; A K Eterovic; U Aytac; M Routbort; V Subbiah; F Janku; M A Davies; S Kopetz; J Mendelsohn; G B Mills; K Chen Journal: Ann Oncol Date: 2016-01-19 Impact factor: 32.976
Authors: B A Carneiro; K A Collier; R J Nagy; S Pamarthy; V Sagar; S Fairclough; J Odegaard; R B Lanman; R Costa; T Taxter; T M Kuzel; A Fan; Y K Chae; M Cristofanilli; M H Hussain; S A Abdulkadir; F J Giles Journal: JCO Precis Oncol Date: 2018-02-14
Authors: Justin I Odegaard; John J Vincent; Stefanie Mortimer; James V Vowles; Bryan C Ulrich; Kimberly C Banks; Stephen R Fairclough; Oliver A Zill; Marcin Sikora; Reza Mokhtari; Diana Abdueva; Rebecca J Nagy; Christine E Lee; Lesli A Kiedrowski; Cloud P Paweletz; Helmy Eltoukhy; Richard B Lanman; Darya I Chudova; AmirAli Talasaz Journal: Clin Cancer Res Date: 2018-04-24 Impact factor: 12.531
Authors: Jeffrey N Weitzel; Elizabeth C Chao; Bita Nehoray; Lily R Van Tongeren; Holly LaDuca; Kathleen R Blazer; Thomas Slavin; D A B M D Facmg; Tina Pesaran; Christina Rybak; Ilana Solomon; Mariana Niell-Swiller; Jill S Dolinsky; Danielle Castillo; Aaron Elliott; Chia-Ling Gau; Virginia Speare; Kory Jasperson Journal: Genet Med Date: 2017-11-30 Impact factor: 8.822
Authors: Roger K Wolff; Michael D Hoffman; Erica C Wolff; Jennifer S Herrick; Lori C Sakoda; Wade S Samowitz; Martha L Slattery Journal: Genes Chromosomes Cancer Date: 2018-04-30 Impact factor: 5.006
Authors: Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson Journal: N Engl J Med Date: 2016-07-06 Impact factor: 91.245
Authors: Anthony J Scott; Molly C Tokaz; Michelle F Jacobs; Arul M Chinnaiyan; Tycel J Phillips; Ryan A Wilcox Journal: Fam Cancer Date: 2020-06-06 Impact factor: 2.375
Authors: Karen L Reckamp; Carolyn E Behrendt; Thomas P Slavin; Stacy W Gray; Danielle K Castillo; Marianna Koczywas; Mihaela C Cristea; Kirsten M Babski; Donna Stearns; Catherine A Marcum; Yenni P Rodriguez; Amie J Hass; Mary M Vecchio; Pamela Mora; Aleck E Cervantes; Sharon R Sand; Rosa M Mejia; Terrence C Tsou; Ravi Salgia; Jeffrey N Weitzel Journal: Cancer Date: 2021-04-15 Impact factor: 6.921